WuXi AppTec Lab Testing Division And Autogenomics Form Strategic Partnership To Introduce Advanced Molecular Diagnostic Technology To China
CARLSBAD, Calif. and SHANGHAI, Sept. 9, 2016 /PRNewswire/ -- WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, today announced that its Laboratory Testing Division (LTD) has entered into an exclusive distributor agreement with AutoGenomics, a US-based molecular diagnostic BioFilmChip® microarray platform company with a current menu of 65 tests.
Under the agreement, LTD will manufacture, register and distribute AutoGenomics' INFINITI® molecular diagnostic systems and related reagent and consumable products inChina. WuXi will license the assembly and manufacturing of the INFINITI® Systems in China.The two companies will also collaborate to develop and commercialize new testing solutions that are specifically designed for China's healthcare market. Chinese patients, doctors and pharmaceutical companies will have more convenient access to world-leading high precision, high sensitivity and highly efficient clinical diagnostic tests.
"We believe our partnership with WuXi AppTec, with its extensive operations in China and its scientific and research and development strengths, will broaden the market for our INFINITI®platform and related genetic tests in China and lead to new and broader healthcare management solutions specifically designed for the healthcare markets in China," said Fareed Kureshy, President and CEO of AutoGenomics.
"It is a milestone event for LTD to introduce AutoGenomics' instruments and diagnostic products to the China market, and an important step forward for WuXi's in vitro diagnostic business," said Dr. Jason Liu, SVP and COO of WuXi LTD. "WuXi has a comprehensive technology platform, extensive global network, and deep understanding of the China healthcare market. We will continue to expand our collaboration and introduce more advanced technologies to China into the future."
The collaboration will also facilitate WuXi's mission to help China's national precision medicine initiative.
"WuXi AppTec is committed to China's healthcare advancement and national precision medicine plan through active collaboration with doctors, scientists, companies and policy makers," added Dr. Ge Li, Chairman and CEO of WuXi AppTec. "We will continue to help advance precision medicine and personalized treatment by introducing more cutting edge technologies, accelerating science from research bench to hospital beds, and ultimately benefiting the general public."
AutoGenomics Inc., a privately held company based in Carlsbad, CA, developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of pharmacogenomics, genetic disorders, infectious disease and oncology. With the discovery of genes and their link to various disease states, the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of precision medicine. www.autogenomics.com.
About WuXi AppTec
WuXiAppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXiAppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling more than 2,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit http://www.wuxiapptec.com
About WuXi LTD
WuXiAppTec Laboratory Testing Division (LTD) provides a comprehensive and integrated testing platform for drug and medical device development. With operations in both China and the U.S., LTD provides services and solutions in analytical chemistry, in vivo pharmacology, drug metabolism and pharmacokinetics, bioanalysis, toxicology, medical device testing and customized antibody and reagent preparation. Please visit http://ltd.wuxiapptec.com/.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wuxi-apptec-lab-testing-division-and-autogenomics-form-strategic-partnership-to-introduce-advanced-molecular-diagnostic-technology-to-china-300325408.html
SOURCE WuXi AppTec